Condition: Glioblastoma Multiforme · Glioblastoma · Glioblastoma Multiforme, Adult · Sponsor: NaviFUS Corporation
This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.
This description comes directly from the study's public registry record.
Sheang-Tze Fung, Ph.D. · 02-25860560 · stfung@navifus.com
Arthur Lung, Ph.D. · arthur.lung@navifus.com
Always discuss trial participation with your own doctor first.
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Linkou Chang Gung Memorial Hospital | Taoyuan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06496971